www.amgenmedinfo.com
866-572-6436
DeLLphi Clinical Trials are available to patients with Small-Cell Lung Cancer (SCLC)
Amgen Oncology is testing the investigational drug tarlatamab to see how safe and effective it is at treating patients who have small-cell lung cancer (SCLC).
DeLLphi-305 (Extensive-Stage SCLC)
DeLLphi-306 (Limited-Stage SCLC)
Underlined terms can be clicked for more information.
There are multiple options to find the trial that’s right for you.
Which trial is right for me?
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.
For patients with extensive-stage SCLC receiving their first course of treatment. Patients with prior limited-stage SCLC may qualify.
Is this trial right for me?
For patients with limited-stage SCLC who have completed chemotherapy and radiation therapy without progression.
Is this trial right for me?
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.